Abeona Therapeutics reported third quarter 2026 net revenue of 13.5 million dollars from ZEVASKYN, its autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, up 18 percent from 11.4 million dollars in the second quarter. Fifteen patient treatments have been completed since launch, six of them in the third quarter. The net loss narrowed to 4.8 million dollars, or 0.08 dollars per share, from 20.2 million dollars in the second quarter, helped by a 6.5 million dollar favourable change in the fair value of warrant liabilities. Cash, equivalents and short-term investments stood at 134.9 million dollars at September 30, down from 146.8 million at June 30 and excluding the financing announced the same day.
The launch infrastructure is still thin, which is the story behind the revenue line. Abeona expanded its qualified treatment centre network to eight sites in the quarter; four centres have now completed patient treatments, after Children’s Hospital of Philadelphia and the University of Texas Medical Branch treated their first patients. New Technology Add-On Payment status under the fiscal 2027 inpatient rule took effect on October 1, giving hospitals supplemental Medicare reimbursement on top of the base payment, though Medicare beneficiaries are only about 10 percent of the patient population. The company also disclosed that revenue was not recognised for one third quarter treatment because the batch failed the identity assay release criterion, a reminder that each treatment is a bespoke manufacturing run with an 84-hour shelf life.
Alongside the results, Abeona acquired APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals. The asset is a Phase 3-ready, once-daily oral disintegrating tablet formulation of fluticasone propionate for eosinophilic esophagitis. Abeona paid no upfront cash: it issued 20 million dollars of its own stock at closing, with 30 million dollars due on FDA approval, up to 30 million dollars more on sales milestones, and tiered royalties from the low to mid teens. A separate 30 million dollar PIPE financing, at gross proceeds before fees, funds general corporate purposes including the new programme.
The deal changes Abeona’s shape more than its size. ZEVASKYN remains the only revenue source and its ramp is measured in single-digit treatments per quarter, while ABO-801 enters a disease area with established competitors and a Phase 3 still to run. The company also holds a carried interest in Ultragenyx’s FAYUVI, approved in September for Sanfilippo syndrome type A, under a 2022 licence carrying milestones and royalties of up to 8 percent. Whether the diversification is worth the dilution depends on execution in two unrelated launches at once.